# Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

> **NCT00383370** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DRUG:** VEGF Trap
- **BIOLOGICAL:** VEGF Trap

## Key facts

- **NCT ID:** NCT00383370
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-09
- **Final completion:** 2008-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383370, "Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00383370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*